| DHAP N = 54 | MINE N = 25 | Fludara + Endoxan N = 13 | CVP N = 8 | GDP N = 5 | CHOP N = 112 | P value |
Age Mean ± SD |
52.53 ± 8.3 |
52.48 ± 8.3 | 44.62.62 ± 13.9 44.63 ± 13.9 |
48 ± 5.88 |
32 ± 2.24 |
45.55 ± 3.2 |
0.000 |
Sex Male Female |
32 (59.3%) 22 (40.7%) |
12 (48%) 13 (52%) |
5 (38.5%) 8 (61.5%) |
0 (0%) 8 (100%) |
0 (0%) 5 (100%) |
52 (46.4%) 60 (53.6%) | 0.01 |
PS 0 1 2 |
5 (9.3%) 33 (61.1%) 16 (29.6%) |
2 (8%) 16 (63%) 7 (28%) |
3 (23.1%) 6 (46.2%) 4 (30.8%) |
0 (0%) 3 (37.5%) 5 (62.5%) |
4 (80%) 0 (0%) 1 (20%) |
11 (9.8%) 54 (48.2%) 47 (42%) | 0.000 |
Pathology B cell NHL T cell NHL |
46 (58.2%) 8 (14.8%) |
18 (72%) 7 (28%) |
10 (76.9%) 3 (23.1%) |
7 (87.5%) 1 (12.5%) |
4 (80%) 1 (20%) |
100 (89.3%) 12 (10.7%) | 0.32 |
LDH mean ± SD |
295.32 ± 123.20 |
277.24 ± 98.39 |
319.92 ± 55.86 |
204 ± 5.3 |
384 ± 8.9 |
325.2 ± 13.2 |
0.162 |
B symptom Positive Negative |
33 (61.1%) 21 (38.9%) |
23 (92%) 2 (8%) |
7 (53.8%) 6 (46.2%) |
5 (62.5%) 3 (37.5%) |
5 (100%) 0 (0%) |
60 (53.6%) 52 (46.4%) | 0.006 |
Stage 1A 1B 2A 2B 3A 3B 4 |
1 (1.9%) 1 (1.9%) 12 (22.2%) 1 (1.9%) 23 (42.6%) 12 (22.2%) 4 (7.4%) |
0 (0%) 4 (16%) 5 (20%) 0 (0%) 12 (48%) 0 (0%) 4 (16%) |
4 (30.8%) 0 (0%) 0 (0%) 0 (0%) 1 (7.7%) 8 (61.5%) 0 (0%) |
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 4 (50%) 4 (50%) |
0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (20%) 4 (80%) 0 (0%) |
1 (0.9%) 1 (0.9%) 23 (20.5%) 6 (5.4%) 41 (36.6%) 13 (11.6%) 27 (24.1%) | 0.000 |
1st line CHOP R-CHOP |
54 (100%) 0 (0%) |
25 (100%) 0 (0%) |
13 (100%) 0 (0%) |
8 (100%) 0 (0%) |
5 (100%) 0 (0%) |
95 (84.8%) 17 (15.2%) | 0.016 |
1st Response Refractory Relapsed Before 1 y After 1 y |
25 (46.3%) 29 (53.7%) 28 (96.5%) 1 (3.4%) |
8 (32%) 17 (30.8%) 6 (35.3%) 11 (64.7%) |
9 (69.2%) 4 (30.8%) 2 (50%) 2 (50%) |
0 (0%) 8 (100%) 5 (62.5%) 3 (37.5%) |
4 (80%) 1 (20%) 0 (0%) 1 (100%) |
67 (59.8%) 45 (40.2%) 18 (40%) 27 (60%) |
0.002
0.89 |
IPI Low risk Low intermediate High intermediate High risk |
7 (13%) 24 (44.4%) 9 (16.7%) 14 (25.9%) |
9 (36%) 11 (44%) 4 (16%) 1 (4%) |
3 (23.1%) 4 (30.8%) 4 (30.8%) 2 (15.4%) |
1 (12.5%) 5 (62.5%) 1 (12.5%) 1 (12.5%) |
4 (80%) 1 (20%) 0 (0%) 0 (0%) |
26 (23.2%) 40 (35.7%) 28 (25%) 18 (16.1%) | 0.05 |